The total value of proposed dividends amounted to EGP 45 million, according to the company’s statement to the Egyptian Exchange (EGX) on Sunday.
It is noteworthy that the company’s capital reaches EGP 50 million distributed over 5 million shares at EGP 10 apiece.
During FY18/19, the pharmaceuticals firm’s profit fell to EGP 112.8 million, compared to EGP 118.2 million in the prior fiscal year, according to the company’s modified unaudited financial results.
All Rights Reserved - Mubasher Info © 2005 - 2019 Provided by SyndiGate Media Inc. (Syndigate.info).




















